Health Secretary Robert F. Kennedy Jr. has urged better and earlier Alzheimer screening while the federal panel charged with evaluating preventive services has not met since March 2025. The contradiction is operational, not rhetorical. [1]
The US Preventive Services Task Force normally has 16 expert volunteers. The Guardian reported at least eight vacancies, two chairs fired and no meeting for more than a year. The panel had planned to consider cognitive-decline screening among 14 topics. [1] An institution cannot review evidence while its seats and calendar remain empty.
Kennedy told Congress in April that screening was critical and called the panel lackadaisical and negligent. Yet his department's administration had prevented meetings and failed to fill vacancies. [1] Advocacy from the secretary is not a recommendation from the task force, and criticism of delay does not replace the review that delay interrupted.
The medical distinction is equally important. A blood biomarker test for P-Tau217 has been cleared for diagnostic use in people older than 50 who show signs and symptoms of Alzheimer disease. It is not cleared as a population-screening program. [1] Diagnostic accuracy among symptomatic patients does not establish the benefits and harms of testing millions of people without symptoms.
Screening needs more than a measurable biomarker. It needs an intended population, a threshold, sensitivity and specificity in that population, a pathway for confirmatory assessment, counseling after uncertain results and evidence that earlier detection improves outcomes enough to outweigh false positives and anxiety. Insurance coverage is another decision, not an automatic consequence of a test reaching the market.
The scale makes those questions urgent. The Guardian cited an estimated 7.4 million Americans aged 65 and older living with Alzheimer disease and about 200,000 diagnosed in middle age. [1] Those are disease-burden estimates. They are not a denominator showing how many asymptomatic adults should receive a blood test or how many would benefit.
Experts interviewed by the Guardian described evidence for broad cognitive screening as mixed. One researcher said the blood tests offered strong diagnostic rather than prognostic value and warned against broad rollout. Another distinguished finding measurable changes in studies from testing at every primary-care visit. [1] That disagreement is precisely what a functioning evidence panel is built to examine.
The panel also links science to public administration. Its draft recommendations invite public comment, identify research gaps and help shape preventive-service coverage. Leaving it idle can therefore slow both the judgment Kennedy demands and the studies needed to improve that judgment.
No authorized X post was recovered, so platform enthusiasm for a blood-test revolution or hostility toward federal experts cannot be claimed. The Guardian emphasizes the political contradiction, but the deeper cost is clinical: urgency without review encourages people to confuse detection with prognosis, recommendation and treatment.
Kennedy may be right that earlier recognition deserves investment. That proposition does not answer whether population screening works. The next receipts are HHS and AHRQ orders, a restored roster and meeting schedule, a reviewed body of evidence, a recommendation and a coverage pathway. Until then, the government is pressing the accelerator while the instrument panel remains dark.
-- NORA WHITFIELD, Chicago